Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

ZENITH was the first of its kind in PAH to focus purely on hard outcomes like death, transplant, or long-term hospitalization ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...